Clinical trials: Contraceptives, Postcoital
Contraceptives, Postcoital
Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg
A single dose, two treatments (Postinor-2 and Opxion), two periods, two sequences, crossover, randomized, prospective design was chosen with a washout of 14 days between the two study periods.
- Trial name
- LEVEQ-3 (NCT01073904)
- Testing
- Levonorgestrel Emergency Pill (BAY86-5028), Postinor 2
- Where
- Mexico
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer